Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | PPARA | Q07869 | 12/20 | 0.47 |
| ▸ | PPARG | P37231 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15655839 | 1.00 | HPGD (0.52) | HPGDNPC1PPARAPPARGGAA | |
| SCHEMBL15655554 | 1.00 | HPGD (0.52) | HPGDNPC1PPARAPPARGGAA | |
| SCHEMBL15656795 | 0.83 | GAA (0.55) | HPGDNPC1PPARAPPARGGAA | |
| SCHEMBL15655693 | 0.80 | HPGD (0.53) | HPGDNPC1PPARAPPARGGAA | |
| SCHEMBL15679907 | 0.78 | RAB9A (0.63) | HPGDNPC1GAASMN1; SMN2ALDH1A1 | |
| SCHEMBL15656009 | 0.77 | LMNA (0.53) | HPGDNPC1GAASMN1; SMN2ALDH1A1 | |
| SCHEMBL15655355 | 0.76 | GAA (0.51) | HPGDNPC1PPARAPPARGGAA | |
| SCHEMBL15654437 | 0.74 | GAA (0.49) | HPGDNPC1PPARAPPARGGAA | |
| SCHEMBL15655691 | 0.74 | RAB9A (0.62) | HPGDNPC1GAASMN1; SMN2ALDH1A1 | |
| SCHEMBL15655911 | 0.73 | RAB9A (0.60) | HPGDNPC1GAASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9801861-B2 | Antimicrobial substituted thiazoles and methods of use | PURDUE RESEARCH FOUNDATION (US) | 2017-10-31 | — | — | US | disclosed |
| US-9801861-B2 | Antimicrobial substituted thiazoles and methods of use | PURDUE RESEARCH FOUNDATION (US) | 2017-10-31 | — | — | US | disclosed |
| US-20160243088-A1 | ANTIMICROBIAL SUBSTITUTED THIAZOLES AND METHODS OF USE | PURDUE RESEARCH FOUNDATION (US) | 2016-08-25 | — | — | US | disclosed |
| US-20160243088-A1 | ANTIMICROBIAL SUBSTITUTED THIAZOLES AND METHODS OF USE | PURDUE RESEARCH FOUNDATION (US) | 2016-08-25 | — | — | US | disclosed |
| US-9353072-B2 | Antimicrobial substituted thiazoles and methods of use | PURDUE RESEARCH FOUNDATION (US) | 2016-05-31 | — | — | US | disclosed |
| US-9353072-B2 | Antimicrobial substituted thiazoles and methods of use | PURDUE RESEARCH FOUNDATION (US) | 2016-05-31 | — | — | US | disclosed |
| US-9353072-B2 | Antimicrobial substituted thiazoles and methods of use | PURDUE RESEARCH FOUNDATION (US) | 2016-05-31 | — | — | US | disclosed |
| US-20140121249-A1 | ANTIMICROBIAL SUBSTITUTED THIAZOLES AND METHODS OF USE | PURDUE RESEARCH FOUNDATION | 2014-05-01 | — | — | US | disclosed |
| US-20140121249-A1 | ANTIMICROBIAL SUBSTITUTED THIAZOLES AND METHODS OF USE | PURDUE RESEARCH FOUNDATION | 2014-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140121249-A1 | ANTIMICROBIAL SUBSTITUTED THIAZOLES AND METHODS OF USE | CLPP, ELANE, NOD2 | HPGD 1785/4885NPC1 538/4885PPARA 183/4885 |
| US-20160243088-A1 | ANTIMICROBIAL SUBSTITUTED THIAZOLES AND METHODS OF USE | CLPP, ELANE, NOD2 | HPGD 1785/4885NPC1 538/4885PPARA 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.